

5 innovative startups receive recognition at Bio Asia 2026

19 February 2026 | News

For Bio Asia 2026, over 120 startups were shortlisted by an eminent jury



At BioAsia 2026, the 23rd edition of Asia's premier life sciences and health-tech forum, held in Hyderabad on 17 and 18 February 2026, five innovative startups- Achala Health Services Private Limited, Exquinz Life Sciences Pvt Ltd, Helex, Natural Solutions & Nutraceuticals Pvt Ltd and Sree Guravey Life Sciences OPC Pvt Ltd, received BioAsia 2026 Innovation Awards.

For Bio Asia 2026, over 120 startups were shortlisted by an eminent jury. 40+ most innovative startups with disruptive contributions across MedTech, Medical Devices, BioPharma, Cell and Gene Therapy, AI and ML, Nutraceuticals, and Biomarkers exhibited their cutting-edge solutions, reinforcing Telangana's position as an innovation hub of life sciences.

Details of the award-winning startups at Bio Asia 2026:

- Achala Health Services** – Founded by T Rajesh Raju, Achala Health is building India's first healthcare-focused Small Language Model (SLM). The AI platform optimises hospital workflows by automating discharge summaries, clinical documentation, claim codification, and contextual clinical search. It uses a proprietary synthetic data engine and a self-evolving reinforcement learning system to reduce documentation time, improve bed turnover, and enhance patient care. The system is designed to be interoperable with EMR, LIMS, RIS, HIS, and pharmacy data and is deployable across Tier 1 and Tier 2 hospitals.
- Exquinz Life Sciences** – Founded by Dr Sree Lakshmi Latha, Exquinz integrates next-generation digital vaccine vial monitors with AI-enabled authentication and real-time tracking. The technology combines a chemical time-temperature

indicator with QR/NFC tagging for authentication and traceability. A mobile application allows scanning, verification, and transmission of data to a secure cloud platform. AI algorithms predict residual vaccine shelf-life and alert stakeholders before potency loss, improving vaccine safety, reducing wastage, and ensuring supply chain transparency in line with WHO and national immunisation standards.

- **Helex** – Founded by Poulami Chaudhuri, Helex develops non-viral gene therapies for renal diseases, including a first-in-class genome editing therapeutic for Autosomal Dominant Polycystic Kidney Disease (ADPKD). Using a proprietary kidney-targeting lipid nanoparticle, the therapy restores PKD1 gene expression, potentially reversing cyst formation. The solution is mutation-agnostic, scalable, and represents a durable, disease-modifying intervention, addressing a significant unmet medical need in India and globally.
- **Natural Solutions & Nutraceuticals** – Founded by Dr Anil Sharma, the company's product Virulina offers a triple-action herbal approach to respiratory viruses, targeting the virus, host response, and inflammation. Preclinical studies demonstrate antiviral activity, immunomodulatory effects, and anti-inflammatory properties, improving patient recovery and supporting holistic care. Virulina is patent-protected and validated for safety and efficacy.
- **Sree Guravey Life Sciences OPC** – Founded by Prathima Deepthi, Sree Guravey Life Sciences develops BioMap Markers for biopsy procedures. The markers feature unique ridges to prevent migration, are ultrasonography-sensitive, biocompatible, non-calcified, and metal-free, ensuring accurate placement and reliable diagnostic outcomes. The innovation enhances clinical accuracy and patient safety across diagnostic procedures.